Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

Astellas ranks in Top 10 of Working Mother Best Companies list

Astellas Ranks in Top 10 of Working Mother Best Companies list Read More

Effie Tozzo

Powering on with the Mitochondria: Kidney Disease & Beyond

By Effie Tozzo, PhD, Senior Vice President, Translational Sciences, Mitobridge, An Astellas Company

Astellas Oncology Announces Grand Prize Winner of 2019 C3 Prize® to Improve Cancer Care

Astellas Oncology Announces Grand Prize Winner of 2019 C3 Prize® to Improve Cancer Care Read More

https://www.astellas.com/us/news/4581

Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy Read More

1

2

3

4

News

Latest

News / Media

Sep 02, 2019

RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology in Oncology

News / Media

Aug 09, 2019

Yokohama City University, Tokyo University of the Arts and Astellas Launched Health Mock Lab. to Create New Digital Healthcare Solutions Using Gamification

News / Media

Aug 06, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

News / Corporate

Dec 05, 2019

Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science

News / Therapeutic Area News

Dec 03, 2019

Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting

News / Corporate

Dec 02, 2019

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer